Skip to main content
SpringerLink
Log in

Belimumab: risk of depression, suicidal ideation

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Health Canada. BENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury Internet Document : 4 Apr 2019. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69506a-eng.php

  2. Health Products Regulatory Authority. Benlysta (Belimumab) - Important Safety Information from GlaxoSmithKline Pharmaceuticals as approved by the HPRA Internet Document : 2 Apr 2019. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/benlysta-(belimumab)---important-safety-information-from-glaxosmithkline-pharmaceuticals-as-approved-by-the-hpra&id=53d20b26-9782-6eee-9b55-ff00008c97d0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Belimumab: risk of depression, suicidal ideation. Reactions Weekly 1748, 2 (2019). https://doi.org/10.1007/s40278-019-59918-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-59918-0

Search

Navigation